Hypersensitivity Reactions to Drugs

Harper's Textbook of Pediatric Dermatology: Third Edition

Volumn 2, Issue , 2011, Pages 1-14

  Ott, Hagen ^a  

^a Catholic Children's Hospital Wilhelmstift   (Germany)

Author keywords

Acute generalized pustulosis; Adverse drug reaction; DRESS syndrome; Drug allergy; Drug hypersensitivity; Fixed drug eruption; Maculopapular exanthema; Toxic epidermal necrolysis

Indexed keywords

EID: 84886527953     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444345384.ch183     Document Type: Chapter

References (159)

1. WHO. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Org Tech Rep Ser 1972; 498: 1-25.
2. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM (ed.) Textbook of Adverse Drug Reactions. Oxford: Oxford University Press, 1977; 10.
3. Johansson SG, Bieber T, Dahl R et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
4. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010; 94: 645-64, xv.
5. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83.
6. Menniti-Ippolito G, Raschetti R, Da CR, Giaquinto C, Cantarutti L. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet 2000; 355: 1613-14.
7. Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting, Arch Dermatol 2000; 136: 849-54.
8. Bourgeois FT, Mandl KD, Valim C, Shannon MW. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics 2009; 124: e744-e750.
9. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts, Arch Dis Child 2009; 94: 724-8.
10. Rebelo GE, Fonseca J, Araujo L, Demoly P. Drug allergy claims in children: from self-reporting to confirmed diagnosis. Clin Exp Allergy 2008; 38: 191-8.
11. Lange L, Koningsbruggen SV, Rietschel E. Questionnaire-based survey of lifetime-prevalence and character of allergic drug reactions in German children. Pediatr Allergy Immunol 2008; 19: 634-8.
12. Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol 2010; 125: S126-S137.
13. Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA(2)LEN/ EDF/WAO guideline: definition, classification and diagnosis of urticaria, Allergy 2009; 64: 1417-26.
14. Mehl A, Wahn U, Niggemann B. Anaphylactic reactions in children-a questionnaire-based survey in Germany. Allergy 2005; 60: 1440-5.
15. de Silva IL, Mehr SS, Tey D, Tang ML. Paediatric anaphylaxis: a 5 year retrospective review, Allergy 2008; 63: 1071-6.
16. Tan EK, Grattan CE. Drug-induced urticaria. Expert Opin Drug Saf 2004; 3: 471-84.
17. Shin HT, Chang MW. Drug eruptions in children. Curr Probl Pediatr 2001; 31: 207-34.
18. Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007; 120: e1082-e1096.
19. Sanchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin North Am 2010; 94: 853-64, xiii.
20. Sanchez-Borges M, Capriles-Behrens E, Caballero-Fonseca F. Hypersensitivity to non-steroidal anti-infl ammatory drugs in childhood. Pediatr Allergy Immunol 2004; 15: 376-80.
21. Kidon MI, Kang LW, Chin CW, Hoon LS, Hugo VB. Nonsteroidal anti-infl ammatory drug hypersensitivity in preschool children. Allergy Asthma Clin Immunol 2007; 3: 114-22.
22. Kidon MI, Kang LW, Chin CW et al. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinfl ammatory drugs among young, Asian, atopic children. Pediatrics 2005; 116: e675-e680.
23. Del CA, Sastre J, Montoro J et al. Use of antihistamines in pediatrics, J Investig Allergol Clin Immunol 2007; 17 (Suppl. 2): 28-40.
24. Shah KN, Honig PJ, Yan AC. " Urticaria multiforme ": a case series and review of acute annular urticarial hypersensitivity syndromes in children, Pediatrics 2007; 119: e1177-e1183.
25. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132: 336-42.
26. Stricker BH, Tijssen JG. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992; 45: 1177-84.
27. Sanklecha MU. Cefaclor induced serum sickness like reaction. Indian J Pediatr 2002; 69: 921.
28. Isaacs D. Serum sickness-like reaction to cefaclor. J Paediatr Child Health 2001; 37: 298-9.
29. Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T. Serum sickness- like syndrome associated with cefaclor therapy. Allergy 1992; 47: 439-40.
30. Hebert AA, Sigman ES, Levy ML. Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol 1991; 25: 805-8.
31. Shraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab. Ann Pharmacother 2009; 43: 383-6.
32. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness- like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120: 972-3.
33. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13: 94-5.
34. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infl iximab. J Emerg Med 2006; 30: 41-4.
35. Baniasadi S, Fahimi F, Mansouri D. Serum sickness-like reaction associated with cefuroxime and ceftriaxone. Ann Pharmacother 2007; 41: 1318-19.
36. Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol 2006; 6: 3.
37. Ralph ED, John M, Rieder MJ, Bombassaro AM. Serum sickness-like reaction possibly associated with meropenem use. Clin Infect Dis 2003; 36: E149-E151.
38. Landau M, Shachar E, Brenner S. Minocycline-induced serum sickness- like reaction. J Eur Acad Dermatol Venereol 2000; 14: 67-8
39. Guharoy SR. Serum sickness secondary to ciprofl oxacin use. Vet Hum Toxicol 1994; 36: 540-1.
40. Parra FM, Perez Elias MJ, Cuevas M, Ferreira A. Serum sickness-like illness associated with rifampicin. Ann Allergy 1994; 73: 123-5.
41. Colton RL, Amir J, Mimouni M, Zeharia A. Serum sickness-like reaction associated with griseofulvin. Ann Pharmacother 2004; 38: 609-11.
42. Park H, Knowles S, Shear NH. Serum sickness-like reaction to itraconazole. Ann Pharmacother 1998; 32: 1249.
43. Waibel KH, Katial RK. Serum sickness-like reaction and bupropion. J Am Acad Child Adolesc Psychiatry 2004; 43: 509.
44. Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol 2003; 56: 583.
45. Shapiro LE, Knowles SR, Shear NH. Fluoxetine-induced serum sickness-like reaction. Ann Pharmacother 1997; 31: 927.
46. Mohammed S, Jamal AZ, Robison LR. Serum sickness-like illness associated with N-acetylcysteine therapy. Ann Pharmacother 1994; 28: 285.
47. Schweitzer DH, van der Wall EE, Bosker HA, Scheffer E, Macfarlane JD. Serum-sickness-like illness as a complication after streptokinase therapy for acute myocardial infarction. Cardiology 1991; 78: 68-71.
48. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125: 805-11.
49. Joubert GI, Hadad K, Matsui D, Gloor J, Rieder MJ. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care, Can J Clin Pharmacol 1999; 6: 197-201.
50. Borch JE, Andersen KE, Bindslev-Jensen C. Cutaneous adverse drug reactions seen at a university hospital department of dermatology. Acta Derm Venereol 2006; 86: 523-7.
51. Fiszenson-Albala F, Auzerie V, Mahe E et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-22.
52. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents-a 6 year series from Chandigarh, India. J Postgrad Med 2001; 47: 95-9.
53. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey, Allergy 1997; 52: 388-93.
54. Yawalkar N. Maculopapular drug eruptions. In: Pichler WJ (ed.) Drug Hypersensitivity. Basel: Karger, 2007; 242-51.
55. Hausmann O, Schnyder B, Pichler WJ. Drug hypersensitivity reactions involving skin. In: Uetrecht J (ed.) Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer, 2010; 30-52.
56. Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007; 120: e1082-e1096.
57. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 1083-4.
58. Ben mM, Leclerc-Mercier S, Blanche P et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88: 131-40.
59. Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol 2009; 26: 536-46.
60. D'Orazio JL. Oxcarbazepine-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Clin Toxicol (Phila) 2008; 46: 1093-4.
61. Dewan AK, Quinonez RA. Allopurinol- induced DRESS syndrome in an adolescent patient. Pediatr Dermatol 2010; 27: 270-3.
62. Vinson AE, Dufort EM, Willis MD, Eberson CP, Harwell JI. Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation-A case of vancomycin- induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline. Pediatr Crit Care Med 2010; 11: e38-e43.
63. Rosenbaum J, Alex G, Roberts H, Orchard D. Drug rash with eosinophilia and systemic symptoms secondary to sulfasalazine. J Paediatr Child Health 2010; 46: 193-6.
64. Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol 2009; 60: 146-9.
65. Santos RP, Ramilo O, Barton T. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. Pediatr Infect Dis J 2007; 26: 1053-6.
66. Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J Dermatolog Treat 2009; 20: 340-3.
67. Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E et al. Amoxicillin-induced fl are in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol 2010; 20: 68-73.
68. Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609-11.
69. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7: 142-60.
70. Mansur AT, Pekcan YS, Goktay F. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol 2008; 47: 1184-9.
71. Eshki M, Allanore L, Musette P et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009; 145: 67-72.
72. Kano Y, Ishida T, Hirahara K, Shiohara T. Visceral involvements and long- term sequelae in drug-induced hypersensitivity syndrome. Med Clin North Am 2010; 94: 743-59, xi.
73. Lens S, Crespo G, Carrion JA, Miquel R, Navasa M. Severe acute hepatitis in the dress syndrome: Report of two cases. Ann Hepatol 2010; 9: 198-201.
74. Mennicke M, Zawodniak A, Keller M et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009; 9: 2197-202.
75. Fujita Y, Hasegawa M, Nabeshima K et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Intern Med 2010; 49: 409-13.
76. Savard S, Desmeules S, Riopel J, Agharazii M. Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis 2009; 54: e17-e20.
77. Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 2005; 64: 155-8.
78. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 2003; 206: 353-6.
79. Cumbo-Nacheli G, Weinberger J, Alkhalil M, Thati N, Baptist AP. Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation? Epilepsia 2008; 49: 2108-12.
80. Halevy S. Acute generalized exanthematous pustulosis, Curr Opin Allergy Clin Immunol 2009; 9: 322-8.
81. Riten K, Shahina Q, Jeannette J, Palma-Diaz MF. A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. Pediatr Dermatol 2009; 26: 623-5.
82. Ozmen S, Misirlioglu ED, Gurkan A, Arda N, Bostanci I. Is acute generalized exanthematous pustulosis an uncommon condition in childhood? Allergy 2010 Nov; 65 (11): 1490-2.
83. Sezer E, Sezer T, Koseoglu D, Filiz NO. Acute generalized exanthematous pustulosis in a child. Pediatr Dermatol 2007; 24: 93-5.
84. Belhadjali H, Ghannouchi N, Njim L et al. Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl. Contact Dermatitis 2008; 58: 247-8.
85. Chiu A, Kohler S, McGuire J, Kimball AB. Cytarabine-induced acute generalized exanthematous pustulosis. J Am Acad Dermatol 2002; 47: 633-5.
86. Ofuji S, Yamamoto O. Acute generalized exanthematous pustulosis associated with a human parvovirus B19 infection. J Dermatol 2007; 34: 121-3.
87. Feio AB, Apetato M, Costa MM, Sa J, Alcantara J. [Acute generalized exanthematous pustulosis due to Coxsackie B4 virus]. Acta Med. Port 1997; 10: 487-91.
88. Haro-Gabaldon V, Sanchez-Sanchez-Vizcaino J, Ruiz-Avila P, Gutierrez-Fernandez J, Linares J, Naranjo-Sintes R. Acute generalized exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol 1996; 35: 735-7.
89. Manzano S, Guggisberg D, Hammann C, Laubscher B. [Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection]. Arch Pediatr 2006; 13: 1230-2.
90. Lim CS, Lim SL. Acute generalized exanthematous pustulosis associated with asymptomatic Mycoplasma pneumoniae infection. Arch Dermatol 2009; 145: 848-9.
91. Sidoroff A, Dunant A, Viboud C et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989-96.
92. Son CH, Lee CU, Roh MS, Lee SK, Kim KH, Yang DK. Acute generalized exanthematous pustulosis as a manifestation of carbamazepine hypersensitivity syndrome. J Investig Allergol Clin Immunol 2008; 18: 461-4.
93. Hausmann O, Schnyder B, Pichler WJ. Drug hypersensitivity reactions involving skin. In: Uetrecht J (ed.) Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer, 2010; 30-52.
94. Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol 2008; 88: 363-5.
95. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell ' s disease). Burns 2010; 36: 152-63.
96. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7: 142-60.
97. Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am 2010; 94: 727-42, x.
98. Levi N, Bastuji-Garin S, Mockenhaupt M et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123: e297-e304.
99. Birch J, Chamlin S, Duerst R, Jacobsohn D. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome in a hematopoietic stem cell transplant recipient. Pediatr Blood Cancer 2008; 50: 1278-9.
100. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 1995; 14: 558-9.
101. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens -Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20: 219-23.
102. Arvidson J, Kildal M, Linde T, Gedeborg R. Toxic epidermal necrolysis and hemolytic uremic syndrome after allogeneic stem-cell transplantation. Pediatr Transplant 2007; 11: 689-93.
103. Takeda H, Mitsuhashi Y, Kondo S, Kato Y, Tajima K. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 1997; 24: 635-41.
104. Hemmige V, Jenkins E, Lee JU, Arora VM. Toxic epidermal necrolysis (TEN) associated with herbal medication use in a patient with systemic lupus erythematosus. J Hosp Med 2010 Oct; 5 (8): 491-3.
105. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 160-4.
106. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens -Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145: 157-62.
107. Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 2010; 36: 22-32.
108. de Prost N, Ingen-Housz-Oro S, Duong T et al. Bacteremia in Stevens -Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89: 28-36.
109. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
110. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-6.
111. Shiga S, Cartotto R. What are the fl uid requirements in toxic epidermal necrolysis? J Burn Care Res 2010; 31: 100-4.
112. Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (Lyell ' s syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Safety 2010; 33: 189-212.
113. Sotozono C, Ueta M, Kinoshita S. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Am J Ophthalmol 2010; 149: 354.
114. Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges 2010; 8: 341-6.
115. Koh MJ, Tay YK. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol 2010; 62: 54-60.
116. Shay E, Khadem JJ, Tseng SC. Efficacy and limitation of sutureless amniotic membrane transplantation for acute toxic epidermal necrolysis. Cornea 2010; 29: 359-61.
117. Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008 Jan; 58 (1): 33-40.
118. Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr 2009; 21: 505-10.
119. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents-a 6-year series from Chandigarh, India. J Postgrad Med 2001; 47: 95-9.
120. Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol 1995; 12: 178-83.
121. Rodriguez-Jimenez B, Dominguez-Ortega J, Gonzalez-Garcia JM, Kindelan-Recarte C. Dimenhydrinate-induced fixed drug eruption in a patient who tolerated other antihistamines. J Investig Allergol Clin Immunol 2009; 19: 334-5.
122. Nussinovitch M, Prais D, Ben-Amitai D, Amir J, Volovitz B. Fixed drug eruption in the genital area in 15 boys. Pediatr Dermatol 2002; 19: 216-19.
123. Pionetti CH, Kien MC, Alonso A. Fixed drug eruption due to loratadine. Allergol Immunopathol (Madr) 2003; 31: 291-3.
124. Dhar S, Kanwar AJ. Fixed drug eruption on the tongue of a 4-year-old boy. Pediatr Dermatol 1995; 12: 51-2.
125. Duong T, Hamel D, Benlahrech S et al. First fixed drug eruption due to teicoplanin with a peri-oral distribution. J Eur Acad Dermatol Venereol 2009; 23: 1107.
126. Gilmore ES, Friedman JS, Morrell DS. Extensive fixed drug eruption secondary to vancomycin. Pediatr Dermatol 2004; 21: 600-2.
127. Morelli JG, Tay YK, Rogers M, Halbert A, Krafchik B, Weston WL. Fixed drug eruptions in children. J Pediatr 1999; 134: 365-7.
128. Ayala F, Nino M, Ayala F, Balato N. Bullous fixed drug eruption induced by paracetamol: report of a case. Dermatitis 2006; 17: 160.
129. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Safety 2005; 4: 837-48.
130. Sarkar R, Kaur C, Kanwar AJ. Extensive fixed drug eruption to nimesulide with cross-sensitivity to sulfonamides in a child. Pediatr Dermatol 2002; 19: 553-4.
131. Li H, Wiederkehr M, Rao B et al. Peculiar unilateral fixed drug eruption of the breast. Int J Dermatol 2002; 41: 96-8.
132. Ozkaya-Bayazit E. Topical provocation in fixed drug eruption due to metamizol and naproxen. Clin Exp Dermatol 2004; 29: 419-22.
133. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Safety 2004; 3: 655-65.
134. Hindioglu U, Sahin S. Nonpigmenting solitary fixed drug eruption caused by pseudoephedrine hydrochloride. J Am Acad Dermatol 1998; 38: 499-500.
135. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9: 316-21.
136. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002; 2: 317-23.
137. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7: 142-60.
138. Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges 2008; 6: 181-8.
139. Wedi B. Fragebogen Medikamenten ü berempfindlichkeit. Allergo Journal 2005; 8: 613-16.
140. Bagg A, Chacko T, Lockey R. Reactions to prick and intradermal skin tests. Ann Allergy Asthma Immunol 2009; 102: 400-2.
141. Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des 2008; 14: 2778-91.
142. Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64: 183-93.
143. Schnyder B. Hauttestungen bei Medikamentenallergien. Allergologie 2009; 9: 302-9.
144. Torres MJ, Blanca M. Importance of skin testing with major and minor determinants of benzylpenicillin in the diagnosis of allergy to betalactams. Statement from the European Network for Drug Allergy concerning AllergoPen withdrawal. Allergy 2006; 61: 910-11.
145. Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64: 183-93.
146. Romano A, Viola M, Bousquet PJ et al. A comparison of the performance of two penicillin reagent kits in the diagnosis of beta-lactam hypersensitivity. Allergy 2007; 62: 53-8.
147. Romano A, Gueant-Rodriguez RM et al. Diagnosing immediate reactions to cephalosporins, Clin Exp Allergy 2005; 35: 1234-42.
148. Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet PJ. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 2008; 122: 521-7.
149. Blanca M, Romano A, Torres MJ et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64: 183-93.
150. Fontaine C, Mayorga C, Bousquet PJ et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy 2007; 62: 47-52.
151. Fernandez TD, Torres MJ, Blanca-Lopez N et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009; 64: 242-8.
152. Blanca M, Mayorga C, Torres MJ et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy 2001; 56: 862-70.
153. Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-63.
154. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol 2010 Aug; 10 (4): 291-6.
155. Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet PJ. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 2008; 122: 521-7.
156. Blanca-Lopez N, Zapatero L, Alonso E et al. Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009; 64: 229-33.
157. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-20.
158. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62: 1439-44.
159. Demoly P, Romano A, Botelho C et al. Determining the negative predictive value of provocation tests with beta-lactams. Allergy 2010; 65: 327-32.